Showing posts with label system. Show all posts
Showing posts with label system. Show all posts

Sunday, June 9, 2013

Should I take extra folic acid to boost my immune system?

Posted May 28, 2013, 2:00 am vitamins

I’m a healthy woman in my 40s. Should I take extra folic acid to boost my immune system?

Folic acid is, essentially, a vitamin. We all need vitamins. Indeed, the word “vitamin” was coined to refer to a substance that was essential to human life. The natural form of folic acid, folate, occurs in some foods, including vegetables, fruits, and dried beans and peas.

Each of us is a collection of about 13 trillion cells. If our cells get sick, we get sick. If our cells get old, we get old. Folate is essential for the production and maintenance of our cells. That’s especially true during rapid periods of growth, such as pregnancy and infancy. Folate is needed to make DNA and RNA, the genetic material that dictates how our cells function, and it helps prevent mutations to DNA that may lead to diseases, including cancer.

Our immune system cells, which are white blood cells, are always in a rapid period of growth. These cells don’t live very long, so they constantly need to be replaced. Folate deficiency can cause anemia — inadequate production of red blood cells. But it doesn’t weaken the immune system sufficiently to make us more vulnerable to infections, for example.

Over the past 30 years, many studies have found that people with high blood levels of a natural substance called homocysteine are at higher risk for heart disease. One easy way to reduce homocysteine levels is by taking folic acid supplements. Studies have not shown that taking folic acid supplements protects most people from heart disease. The exception is people born with a genetic defect that causes high homocysteine levels. I’m one of them; I take folic acid every day.

For most healthy adults, the Recommended Dietary Allowance (RDA) of folate is 400 micrograms (mcg) a day. Pregnant women should take more: 600 mcg a day. The extra folate helps to reduce the risk of neural tube defects, a serious malformation of the spine, skull or brain in the baby.

Experts advise against getting more than 1,000 mcg per day of folic acid from supplements or fortified foods. You’re unlikely to suffer any ill effects even if you exceed that limit, because your body excretes excess folic acid in the urine. Still, there might be long-term health effects that we don’t yet know about.

On the other hand, there’s no health risk associated with getting plenty of naturally occurring folate from foods. Get as much of your daily requirement as you can from a healthy diet. Good food sources of folate include spinach, asparagus, rice, green peas, broccoli and great northern beans. Many breads, cereals, flours, cornmeal, pastas, rice and other grains are enriched with folic acid.

If you’re not getting enough folate from foods, take a multivitamin that contains 400 mcg of folic acid.

window.fbAsyncInit = function() { FB.init({appId: "199616670120169", status: true, cookie: true, xfbml: true});}; (function() { var e = document.createElement("script"); e.async = true; e.src = document.location.protocol + "//connect.facebook.net/en_US/all.js"; document.getElementById("fb-root").appendChild(e);}());Share

View the original article here

Friday, May 24, 2013

New Drug May Help Immune System Fight Cancer

Early study found tumor reduction in several forms of the diseaseEarly study found tumor reduction in several

By Brenda Goodman

HealthDay Reporter

THURSDAY, May 16 (HealthDay News) -- An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows.

The drug binds to a protein called PD-L1 that sits on the surface of cancer cells and makes them invisible to the immune system, almost like a cloaking device.

"That [the protein] allows the tumor cell to grow unchecked and cause harm to the patient," said study author Dr. Roy Herbst, chief of medical oncology at Yale University.

But with the protein blocked, the immune system can see and destroy cancer cells.

Of 140 patients in the pilot safety study, 29 (or 21 percent) initially saw significant tumor shrinkage after at least three months on the medication. Researchers say 26 patients have continued to respond over time, including some who have been on the drug for more than a year. One patient saw tumors disappear completely.

The drug also seems to work on a wide range of cancers, including some of the toughest to treat, including non-small cell lung cancer, melanoma skin cancer, colorectal cancer, kidney cancer and stomach cancer.

"This has all the characteristics of a really amazing drug," said Herbst, who has been testing new cancer medications for two decades. "I can count on one hand the number of times I've seen response rates like this."

The study was funded by Genentech/Roche, the company that is developing the drug. The results were presented at a Wednesday news conference organized by the American Society of Clinical Oncology in advance of its annual meeting, which starts May 31 in Chicago.

Study results presented at medical meetings are considered preliminary because they have not been subjected to the rigorous scrutiny required for publication in a medical journal.

At least four other companies -- Merck, Bristol-Meyers Squibb, MedImmune and Amplimmune -- also are racing to develop drugs that target PD-L1 or the molecule that binds to it (PD-1).

"I don't think in the history of cancer therapy have you had five or more companies virtually simultaneously developing antibodies targeted at the same pathway," said Dr. Drew Pardoll, co-director of cancer immunology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, in Baltimore.

Pardoll is testing a drug that targets PD-1 for Bristol-Myers Squibb. He was not involved in the current study.

The drugs are part of a wave of new treatments that work by spurring the immune system to take on tumors. These drugs are building on the successes of medications like Provenge, the first cancer immunotherapy, which was approved in 2010 to treat prostate tumors, and Yervoy, which was approved in 2011 to treat metastatic melanoma.


View the original article here

Friday, December 21, 2012

A journey through Steve's digestive system

Howdy, Nerd Herd. I'm trying something a little different today. Here's a little video explaining how we digest food. Let me know what you think.

Posted byDenis Fayeat12:21 PM

View the Original article